Novo Nordisk A/S (NYSE:NVO) Shares Acquired by Citizens Financial Group Inc. RI

Citizens Financial Group Inc. RI increased its stake in Novo Nordisk A/S (NYSE:NVO) by 1.8% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 13,703 shares of the company’s stock after acquiring an additional 239 shares during the period. Citizens Financial Group Inc. RI’s holdings in Novo Nordisk A/S were worth $1,418,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Westside Investment Management Inc. raised its stake in shares of Novo Nordisk A/S by 83.3% in the third quarter. Westside Investment Management Inc. now owns 1,428 shares of the company’s stock valued at $130,000 after acquiring an additional 649 shares in the last quarter. Kranot Hishtalmut Le Morim Tichoniim Havera Menahelet LTD purchased a new position in Novo Nordisk A/S in the third quarter valued at $2,408,000. Lazard Asset Management LLC increased its holdings in Novo Nordisk A/S by 182.2% in the third quarter. Lazard Asset Management LLC now owns 1,494,214 shares of the company’s stock valued at $135,883,000 after buying an additional 964,640 shares during the last quarter. CENTRAL TRUST Co increased its holdings in Novo Nordisk A/S by 111.6% in the third quarter. CENTRAL TRUST Co now owns 6,004 shares of the company’s stock valued at $546,000 after buying an additional 3,166 shares during the last quarter. Finally, Ieq Capital LLC increased its holdings in Novo Nordisk A/S by 136.6% in the third quarter. Ieq Capital LLC now owns 27,474 shares of the company’s stock valued at $2,498,000 after buying an additional 15,860 shares during the last quarter. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on NVO shares. Morgan Stanley started coverage on Novo Nordisk A/S in a report on Tuesday, January 23rd. They issued an “overweight” rating and a $120.00 target price on the stock. Cantor Fitzgerald reissued an “overweight” rating and issued a $160.00 target price on shares of Novo Nordisk A/S in a report on Thursday, April 18th. UBS Group began coverage on Novo Nordisk A/S in a report on Tuesday, January 16th. They issued a “neutral” rating on the stock. Finally, BMO Capital Markets started coverage on Novo Nordisk A/S in a report on Friday, April 12th. They set an “outperform” rating and a $163.00 price objective on the stock. Two research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $133.60.

Novo Nordisk A/S Stock Up 0.8 %

NVO opened at $126.85 on Friday. The business’s 50-day simple moving average is $126.86 and its 200-day simple moving average is $112.11. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.64 and a current ratio of 0.82. Novo Nordisk A/S has a one year low of $75.56 and a one year high of $138.28. The stock has a market capitalization of $569.24 billion, a P/E ratio of 46.89, a price-to-earnings-growth ratio of 2.12 and a beta of 0.41.

Novo Nordisk A/S (NYSE:NVO) last posted its earnings results on Wednesday, January 31st. The company reported $0.71 EPS for the quarter, topping analysts’ consensus estimates of $0.66 by $0.05. Novo Nordisk A/S had a return on equity of 90.36% and a net margin of 36.03%. The business had revenue of $9.51 billion for the quarter, compared to analysts’ expectations of $9.14 billion. Analysts anticipate that Novo Nordisk A/S will post 3.32 EPS for the current year.

Novo Nordisk A/S Increases Dividend

The business also recently declared a Semi-Annual dividend, which was paid on Tuesday, April 2nd. Investors of record on Monday, March 25th were given a $0.664 dividend. This represents a yield of 0.9%. The ex-dividend date was Friday, March 22nd. This is a boost from Novo Nordisk A/S’s previous Semi-Annual dividend of $0.22. Novo Nordisk A/S’s payout ratio is 49.17%.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.